Restoration of IGFBP-rP1 increases radiosensitivity and chemosensitivity in hormone-refractory human prostate cancer

Hiroshima Journal of Medical Sciences

Volumn 62, Issue 1, 2013, Pages 13-19

  Seki, Mitsuhiro ^a,b   Teishima, Jun ^a   Mochizuki, Hideki ^c   Mutaguchi, Kazuaki ^d   Yasumoto, Hiroaki ^e   Oka, Kiyotaka ^a   Nagamatsu, Hirotaka ^a   Shoji, Koichi ^a   Matsubara, Akio ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b MATSUYAMA RED CROSS HOSPITAL   (Japan)

^c Miyoshi Central Hospital   (Japan)

^d Nakatsu Daiichi Hospital   (Japan)

^e SHIMANE UNIVERSITY   (Japan)

Author keywords

Docetaxel; IGFBP rP1; Prostate cancer; Radiosensitivity

Indexed keywords

DOCETAXEL; INSULIN LIKE GROWTH FACTOR BINDING PROTEIN RELATED PROTEIN 1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CASTRATION RESISTANT PROSTATE CANCER; CHEMOSENSITIVITY; CLONOGENIC ASSAY; EXPRESSION VECTOR; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IRRADIATION; MALE; MOUSE; NONHUMAN; RADIATION DOSE; RADIOSENSITIVITY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG RESISTANCE, NEOPLASM; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PROSTATIC NEOPLASMS; TAXOIDS; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875856460     PISSN: 00182052     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Binkert, C., Landwehr, J., Mary, J. L., Schwander, J. and Heinrich, G. 1989. Cloning, sequence analysis and expression of a cDNA encoding a novel insulin-like growth factor binding protein (IGFBP-2). EMBO J. 8: 2497-2502. (Pubitemid 19273331)
2. Canil, C.M., Moore, M.J., Winquist, E., Baets, T., Pollak, M., Chi, K.N., Berry, S., Ernst, D.S., Douglas, L., Brundage, M., Fisher, B., McKenna, A. and Seymour, L. 2005. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J. Clin. Oncol. 23: 455-460. (Pubitemid 46224221)
3. Cariani, E., Lasserre, C., Seurin, D., Hamelin, B., Kemeny, F., Franco, D., Czech, M. P., Ullrich, A. and Brechot, C. 1988. Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res. 48: 6844-6849. (Pubitemid 19012216)
4. de Bono, J.S., Bellmunt, J., Attend, G., Droz, J.P., Millar, K., Flechon, A., Sternberg, C., Parker, C., Zugmaier, G., Hersberger-Gimenez, V., Cockey, L., Mason, M. and Graham, J. 2007. Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-native patients with hormone-refractory prostate cancer. J. Clin. Oncol. 25: 257-262. (Pubitemid 350003013)
5. Eisenberberger, M.A. and Carducci, M. 2007. Treatment of hormone-refractory prostate cancer, p. 3101-3117. In A.J. Wein, L.R. Kavoussi, A.C. Novick, A.W. Partin and C.A. Peters (eds.). Campbell-Walsh Urology, 9th ed. Saunders, Philadelphia.
6. Hwa, V., Oh, Y. and Rosenfeld, R. G. 1999. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr. Rev. 20: 761-787. (Pubitemid 30648894)
7. Innocente, S. A., Abrahamson, J. L., Cogswell, J. P. and Lee, J. M. 1999. p53 regulates a G2 checkpoint through cyclin B1. Proc. Natl. Acad. Sci. USA 96: 2147-2152. (Pubitemid 29117882)
8. Kaighn, M.E., Lechner, J.F., Narayan, K.S. and Jones, L.W. 1978. Prostate carcinoma: Tissue culture cell lines. Natl. Cancer Inst. Monogr. 49: 17-21. (Pubitemid 9152618)
9. Kiefer, M. C., Ioh, R. S., Bauer, D. M. and Zapf, J. 1991. Molecular cloning of a new human insulin-like growth factor binding protein. Biochem. Biophys. Res. Commun. 176: 219-225.
10. Kiefer, M. C., Masiarz, F. R., Bauer, D. M. and Zapf, J. 1991. Identification and molecular cloning of two new 30-kDa insulin-like growth factor binding proteins isolated from adult human serum. J. Biol. Chem. 266: 9043-9049. (Pubitemid 21906616)
11. Kim, H. S., Nagalla, S. R., Oh, Y., Wilson, E., Roberts, C. T., Jr. and Rosenfeld, R. G. 1997. Identification of a family of low-affinity insulin-like growth factor binding proteins (IGFBPs): characterization of connective tissue growth factor as a member of the IGFBP superfamily. Proc. Natl. Acad. Sci. USA 94: 12981-12986. (Pubitemid 27518462)
12. LaTour, D., Mohan, S., Linkhart, T. A., Baylink, D. J. and Strong, D. D. 1990. Inhibitory insulin-like growth factor-binding protein: cloning, complete sequence, and physiological regulation. Mol. Endocrinol. 4: 1806-1814.
13. Lebedeva, I.V., Sarkar, D., Su, Z.Z., Kitada, S., Dent, P., Stein. C.A., Reed, J.C. and Fisher, P.B. 2003. Bcl-2 and Bcl-x(L) differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24. Oncogene 22: 8758-8773. (Pubitemid 38010500)
14. Lee, Y. L., Hintz, R. L., James, P. M., Lee, P. D., Shively, J. E. and Powell, D.R. 1988. Insulin-like growth factor (IGF) binding protein complementary deoxyribonucleic acid from human HEP G2 hepatoma cells: predicted protein sequence suggests an IGF binding domain different from those of the IGF-I and IGF-II receptors. Mol. Endocrinol. 2: 404-411.
15. Li, Y., Li, X., Hussain, M. and Sarkar, F.H. 2004. Regulation of microtubule, apoptosis, and cell cycle -related genes by prostate cancer cells analyzed by microarray. Neoplasma 6: 158-167. (Pubitemid 38544604)
16. Murphy, M., Pykett, M. J., Harnish, P., Zang, K. D. and George, D. L. 1993. Identification and characterization of genes differentially expressed in meningiomas. Cell Growth Differ. 4: 715-722.
17. Mutaguchi, K., Yasumoto, H., Mita, K., Matsubara, A., Shiina, H., Igawa, M., Dahiya, R. and Usui, T. 2003. Restoration of insulin-like growth factor binding protein-related protein 1 has a tumor-suppressive activity through induction of apoptosis in human prostate cancer. Cancer Res. 63: 7717-7723. (Pubitemid 37466702)
18. National Cancer Institute. Bethesda Clinical Trials. Available from:http://www.cancer.gov/clinicaltrials. (cited 2007 September 17).
19. Oh, Y., Nagalla, S. R., Yamanaka, Y., Kim, H. S., Wilson, E. and Rosenfeld, R. G. 1996. Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7. Recombinant human mac25 protein specifically binds IGF-I and -II. J. Biol. Chem. 271: 30322-30325.
20. Ryoichi, S., Yoshitaka, K., Takahiko, S., Takahiko, M. and Kiyotaka, H. 2006. Effectiveness of taxane-based chemotherapy against hormone-refractory prostate carcinoma. Hinyokika Kiyo 52: 481-485.
21. Shimasaki, S., Shimonaka, M., Zhang, H. P. and Ling, N. 1991. Identification of five different insulin-like growth factor binding proteins (IGFBPs) from adult rat serum and molecular cloning of a novel IGFBP-5 in rat and human. J. Biol. Chem. 266: 10646-10653. (Pubitemid 21906850)
22. Shimasaki, S. and Ling, N. 1991. Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5 and -6). Prog. Growth Factor Res. 3: 243-266. (Pubitemid 121007608)
23. Tennant, M. K., Thrasher, J. B., Twomey, P. A., Drivdahl, R. H., Birnbaum, R. S. and Plymate, S. R. 1996. Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J. Clin. Endocrinol. Metab. 81: 3774-3782. (Pubitemid 26339953)
24. van Bokhoven, A., Varella-Garcia, M., Korch, C., Johannes, W.U., Smith, E.E., Miller, G.J. and Lucia, M.S. 2003. Molecular characterization of human prostare carcinoma cell lines. Prostate 57:205-225. (Pubitemid 37267805)
25. Wajapeyee, N., Serra, R.W., Zhu, X., Mahalingan, M. and Green, M.R. 2008. Oncogenic BRAF Induces Senescence and Apoptosis through Pathways Medicated by the Secreted Protein IGFBP7. Cell 132: 363-374. (Pubitemid 351191995)
26. Wandji, S. A., Gadsby, J. E., Barber, J. A. and Hammond, J. M. 2000. Messenger ribonucleic acids for MAC25 and connective tissue growth factor (CTGF) are inversely regulated during folliculogenesis and early luteogenesis. Endocrinology 141: 2648-2657. (Pubitemid 32269086)
27. Ziada, A., Barquawki, A., Globe, L.M., Varella-Garcia, M., Crighton, F., Majeski, S., Rosenblum, M., Kane, M., Chen, L. and Crawford, E.D. 2004. The use of trastuzumab in the treatment of hormone-refractory prostate cancer; phase II trial. Prostate 60: 332-337. (Pubitemid 39050653)